Kasumi-3 In Vitro RNA Expression Analysis Assay (Cap Analysis)

This assay is to provide Kasumi-3-based In Vitro RNA Expression Analysis Assay (Cap Analysis) to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

Kasumi-3

Human

The cell line was established from the blast cells of a myeloperoxidase-negative acute leukemia patient.
Treatment with either interleukin (IL)-2, IL-3, IL-4, granulocyte-macrophage colony-stimulating factor (GMCSF) or stem cell factor induced the proliferation, characteristic of undifferentiated leukemia.

Acute Myeloblastic Leukemia; AML

Oncology

In Vitro RNA Expression Analysis Assay (Cap Analysis)

Kasumi-3-cell based In Vitro RNA Expression Analysis Assay (Cap Analysis)

Cap analysis gene expression involves the sequencing of PCR-amplified cDNA tags obtained from the 5' end of mRNA. For the identification of starting sites of transcription, the cap analysis gene expression tech nique has become a useful platform.

Gene and Protein Expression Assays

Following transcription, primary transcript RNA is converted into mature RNA by post-transcriptional modifications. Post-transcriptional modification includes three major steps namely the addition of a 5'cap, addition of a 3'polyadenylation tail and RNA splicing. Stability of RNA has been considered as very important for gene expression and proteins at the post-transcriptional level.